A Novel Recombinant Peste des Petits Ruminants-Canine Adenovirus Vaccine Elicits Long-Lasting Neutralizing Antibody Response against PPR in Goats

Junling Qin1,2, Hainan Huang2,4, Yang Ruan2,3, Xiaoqiang Hou2, Songtao Yang2, Chengyu Wang2, Geng Huang2, Tiecheng Wang2, Na Feng2, Yuwei Gao2, Xianzhu Xia1,2*

1 College of Animal Science and Veterinary Medicine, Agricultural Division, Jilin University, Changchun, People’s Republic of China, 2 Veterinary Institute, Academy of Military Medical Sciences, Changchun, People’s Republic of China, 3 College of Animal Science and Technology, Jilin Agricultural University, Changchun, People’s Republic of China, 4 Academy of Animal Science and Veterinary Medicine of Jilin Province, Jilin, Changchun, People’s Republic of China

Abstract

Background: Peste des petits ruminants (PPR) is a highly contagious infectious disease of goats, sheep and small wild ruminant species with high morbidity and mortality rates. The Peste des petits ruminants virus (PPRV) expresses a hemagglutinin (H) glycoprotein on its outer envelope that is crucial for viral attachment to host cells and represents a key antigen for inducing the host immune response.

Methodology/Principal Findings: To determine whether H can be exploited to generate an effective PPRV vaccine, a replication-competent recombinant canine adenovirus type-2 (CAV-2) expressing the H gene of PPRV (China/Tibet strain) was constructed by the in vitro ligation method. The H expression cassette, including the human cytomegalovirus (hCMV) promoter/enhancer and the BGH early mRNA polyadenylation signal, was inserted into the SspI site of the E3 region, which is not essential for proliferation of CAV-2. Infectious recombinant rCAV-2-PPRV-H virus was generated in transfected MDCK cells and used to immunize goats. All vaccinated animals produced antibodies upon primary injection that were effective in neutralizing PPRV in vitro. Higher antibody titer was obtained following booster inoculation, and the antibody was detectable in goats for at least seven months. No serious recombinant virus-related adverse effect was observed in immunized animals and no adenovirus could be isolated from the urine or feces of vaccinated animals. Results showed that the recombinant virus was safe and could stimulate a long-lasting immune response in goats.

Conclusions/Significance: This strategy not only provides an effective PPR vaccine candidate for goats but may be a valuable mean by which to differentiate infected from vaccinated animals (the so-called DIVA approach).

Introduction

Peste des petits ruminants (PPR) is an acute and highly contagious disease of small ruminants, particularly affecting goats and sheep. Disease onset is characterized by fever and somnolence; within a few days, mucosal erosions occur, accompanied by oral and ocular discharge, diarrhea, and symptoms of pneumonia. The disease may resolve after a prolonged convalescent period, but more frequently leads to death [1]. PPR was first described in Côte d’Ivoire as a fatal disease of small ruminants that resembled rinderpest of cattle. Since then, PPR has spread throughout west and sub-Saharan Africa, the Middle East, the Indian subcontinent, Turkey, some countries in Central Asia, and China [2–9]. Currently, PPR is responsible for significant economic losses in goats and sheep productivity in the endemic regions.

PPR is caused by Peste des petits ruminant virus (PPRV), a member of the genus Morbillivirus, family Paramyxoviridae [10,11]. PPRV, like other morbilliviruses, is an enveloped, nonsegmented negative-strand RNA virus. PPRV expresses two external glycoproteins, fusion (F) and hemagglutinin (H), which mediate infectivity. The H protein binds to its cognate receptor on the host cell during the first step of the viral infection process; as such, it acts as a major antigen that stimulates a protective immune response in the host [12–14]. PPR has been controlled for many years by the use of a rinderpest virus (RPV) tissue culture-adapted vaccine [13]. However, the remarkable success of the global rinderpest eradication program has led to the RPV vaccine being banned from use within rinderpest-free zones; the fear is used in any species, including the PPRV-susceptible small ruminants, would hinder the establishment of the serologically negative population.
In response to this ban, a homologous PPR vaccine was produced by passaging the Nigeria 75/1 strain of PPRV 63 times in Vero cells [16], and is now being introduced into some PPR-endemic regions. While this vaccine produces a sufficient PPR neutralizing response, it is not optimal for two main reasons. First, PPRV, like all members of the family Paramyxoviridae, is very heat sensitive and its endemic areas are nearly all in hot climates. Second, the live attenuated PPRV vaccine generates a broad range of immune responses to viral proteins, making it difficult to serologically distinguish vaccinated animals from those naturally infected. Ultimately, sero-epidemiological surveillance of the disease is impossible in endemic areas where a vaccination program has been or is being implemented [17]. Thus, the live attenuated tissue-culture approach needs to be replaced by a vaccine strategy that will facilitate differentiating infected from vaccinated animals, the so-called “DIVA” vaccines [18].

Over the past decade, adenoviruses have emerged as particularly promising vaccine delivery vehicles. They are double-stranded DNA viruses with high genetic stability, exhibiting no mutations or insertion/deletions after multiple rounds of replication in vivo. Furthermore, they do not integrate into the genome of the infected host, and consequently present less of a safety concern for gene delivery since there is little risk of insertional mutagenesis and expression of potentially toxic or deleterious gene products [19–21]. Due to their nonenveloped structure, adenoviruses are physically stable and can withstand lyophilization, suggesting a convenient means for storage, transport, and vaccine formulation that is amenable to global distribution.

Two serotypes of canine adenovirus (CAV) have been isolated. Both CAV-1 and CAV-2 are associated with mild upper respiratory tract infections in dogs, and effective and safe live-modified vaccines are available for routine vaccination of dogs against both. The structure, replication, and transcription of CAV-2 are very well-characterized and it has been more extensively utilized for vector development [22]. When foreign genes are inserted into the non-essential E3 region of CAV-2, replication of the recombinant virus is not impacted, resulting in high virus titers and high-level gene expression [23,24]. Here, we describe the development of a recombinant canine adenovirus type-2 delivery vector expressing the H gene of PPRV and its utility as a vaccine in experimental goats.

**Results**

**Identification of Recombinant virus CAV-2-H**

We successfully generated a recombinant virus rCAV-2-PPRV-H expressing the PPRV H protein. The H gene expression cassette was subcloned into the E3 region of the pPolyII-CAV-2 plasmid, generating a recombinant genome pPolyII-CAV-ΔE3-H (Fig. 1). The identification of the plasmid pVAX-H, pVAXΔE3-H and pPolyII-CAV-ΔE3-H by restriction endonuclease digestion confirmed that the H gene and its expression cassette were included in the recombinant virus (data not shown). Eleven days after transfection, typical CPE (grape-cluster-like cells) was observed under a microscope. Adenovirus-like particles were observed under the electron microscope. The growth characteristics of the recombinant virus were similar to that of the canine adenovirus vaccine strain YCA18. The TCID50 of the rCAV-2-PPRV-H virus was assayed and calculated to be 10^7.14/mL. This virus hemagglutinates human red blood cells and has an HA titer of 1:2^5, which is similar to the titer of the canine adenovirus vaccine strain YCA18. The genome of rCAV-2-PPRV-H was analyzed for genetic stability by restriction enzyme analysis and found to retain the correct genome structure at the 30th serial passage (data not shown).

**Western Blotting**

Recombinant adenovirus-infected MDCK cell lysates were examined by Western blotting and compared with results from the negative control canine adenovirus vaccine strain YCA18. Immunoreactivity of H protein (approximately 70 kD) was found in recombinant adenovirus-infected cell lysates, but not in vaccine strain YCA18 (Fig. 2), indicating that the expressed H protein retained its antigenic reactivity.

At passage 30, the results of RT-PCR detection of H protein of PPRV and Western blotting analysis of H protein expressed by recombinant virus were the same (data not shown). All results indicated that the recombinant virus was stable enough to maintain its genetic integrity.

**Immunofluorescence**

The cellular localization of the H protein expressed by the recombinant adenovirus was investigated immunologically using fixed MDCK cells. H protein expression was readily detected on the surface of MDCK cells infected with CAV-2-PPRV-H (Fig. 3).

**Antibody Assays**

In test goats (The designs of the animal experiments are shown in Table 1), neutralizing antibody titers against PPRV at week 3 after the primary vaccination ranged from 1:52–1:64 with rCAV-2-PPRV-H, 1:64–1:120 with the attenuated PPR vaccine, and <1:2 with CAV-2 injection. At weeks 5–6 (two to three weeks after the booster injection) goats who received rCAV-2-PPRV-H exhibited the highest neutralizing titers against H protein. At thirty weeks after primary injection, at the end of the trial, titers were still above the protective level of 1:10, which indicated that the antibody may persist for a longer time. Comparatively, neutralizing antibody titers induced by the attenuated PPR vaccine reached higher levels than those induced by rCAV-2-PPRV-H from week 2 after the primary vaccination and onward (Table 2).

The HI antibodies against CAV-2 continually increased from week 2 after vaccination, which corresponded with the appearance of PPRV neutralizing antibody; however, the increase of the PPRV neutralizing antibody was more gradual. The highest HI titer of the goat serum was 1:1024, which dropped to 1:64 by week 30 (Table 3).

**Lymphocyte Proliferation Responses**

All the test groups of goats produced robust lymphoproliferative responses, as compared to the PBS control (P<0.05); however, there was no significant difference in the responses between the goats immunized with attenuated PPRV vaccine, rCAV-2-PPRV-H, or CAV-2 (P>0.05) (Table 4).

**Discussion**

Attenuated canine adenovirus type 2 has proved to be an effective vaccine strain used for prevention of canine hepatitis and infectious laryngotracheitis. Although canine adenovirus is a natural pathogen of dogs, it replicates efficiently in goats following inoculation by various routes, including subcutaneous and intramuscular (in our preliminary experiment). Attenuated CAV-2 has also been shown to be safe in other animals, including cats, foxes and swine [25–27]. As with human adenoviruses, a CAV-2 expression vector with a deleted E3 has some advantageous features for gene delivery applications: it replicates efficiently to
Figure 1. Schematic diagram showing the construction strategy of the recombinant virus rCAV-2-PPRV-H. Cassette expression is under
the control of the CMV promotor.
doi:10.1371/journal.pone.0037170.g001

A Novel Recombinant Vaccine against PPR

high titers, provides large cloning space, permits the expression of recombinant proteins in most mammalian cell lines and tissues, and accurately expresses and modifies recombinant proteins. Another important advantage of CAV-2 is the fact that as a natural canine pathogen there are no pre-existing, maternally-derived antibodies in livestock, which could otherwise interfere with vaccine efficacy in young and growing goats.

As a feasibility study, evaluation of the safety of the vaccine is an important concern. Regardless of efficacy, a recombinant virus must cause minimal to no adverse effects in experimental animals. The rCAV-2-PPRV-H could not be isolated from the urine or feces of vaccinated goats, up to the end of the monitoring period on day 35 post-inoculation. This finding further indicated that the recombinant virus could not be shed through urine and feces of immunized goats to contaminate the environment during this period. In another experiment (data not shown), we checked the horizontal infection rates of the recombinant virus by evaluating goats in close contact (living in the same yards) with vaccinated goats; antibodies against CAV-2 or PPRV were not detected in the in-contact control animals, further ruling out the possibility of rCAV-2-PPRV-H shedding from experimental animals with the recombinant virus.

In order to analyze which immunization route could be better and more efficient to enhance high level neutralizing antibody, we also investigated different routes of administration for the recombinant virus. However, the only effective route of inoculation for eliciting neutralizing antibodies against PPRV in goats was intramuscular injection. The oral inoculation and intranasal administration did not produce any antibodies against either adenovirus or PPRV (data not shown), indicating that no effective immune reaction can be elicited by these two routes. This suggested that goats could not be naturally infected with CAV-2, especially since there was no antibody against CAV-2 in goats before administration. Avoiding interference of pre-existing antibodies is an important requirement for successful recombinant vaccine; the fact that there is no chance of pre-existing antibody interference to CAV-2 in goats enhances the potential of this adenovirus vaccine to stimulate a strong and efficient immune response.

The hemagglutinin protein of PPRV has been shown to play a crucial role in stimulating antibody responses against PPR infection [29]. According to standards of OIE, a VNT of 10 is the minimum value for quality control and efficacy evaluation for the PPR-like attenuated vaccine, Nig/75/1 [29]. In order to enhance the level of immune responses of rCAV-2-PPRV-H in our experimental goats, immunizations with rCAV-2-PPRV-H were carried out twice with the same dose at 21-day intervals. The titers of neutralizing antibody against PPRV induced by rCAV-2-PPRV-H were significantly enhanced after booster of rCAV-2-PPRV-H. A single immunization of rCAV-2-PPRV-H induced the antibody against PPRV up to 1:32-1:64 within three weeks. After the booster, a titer of 1:64-1:128 was achieved, which surpassed the minimum required level for PPRV by a considerable margin.

Although the antibody response against PPRV has largely been considered the most important factor in efficient protection, good cellular immunity stimulated by a vaccine would also enhance this efficiency and persistence, as well as induce more durable immunity. Therefore, we also investigated the cell-mediated immune response in goats by lymphocyte proliferation assay. Live attenuated vaccines are known to be efficient in inducing long-lasting immunity via cellular and humoral immune responses [30,31]. The data from the lymphocyte proliferation assay showed that, as compared with the negative control, the three groups immunized with attenuated PPRV, rCAV-2-PPRV-H, and CAV-2 stimulated similar high cellular immune responses; in addition, the cell-mediated immunity efficiencies between the attenuated PPRV group and rCAV-2-PPRV-H group were nearly identical. Even if the VNA titer of the recombinant virus vaccinated animal is undetectable, the animal may still be protected against PPR challenge [32]. This further demonstrated that cell-mediated immunity plays a very important role in PPR vaccines.

In summary, a novel recombinant canine adenovirus expressing the H protein of PPRV was constructed, and the recombinant virus rCAV-2-PPRV-H expressed the H protein efficiently and induced humoral and cellular immunity against PPRV in goats. This adenovirus vector might be an attractive candidate DIVA vaccine for preventing the disease associated with PPRV infection and facilitating sero-epidemiological surveillance of PPR.

Materials and Methods

Cells, viruses, Genes and Plasmids

Madin-Darby canine kidney (MDCK) cells (American Type Culture Collection (ATCC), CCL-34) were cultured in Dulbecco’s Modified Essential Medium (DMEM; Invitrogen, USA) containing 10% (v/v) heat-inactivated fetal bovine serum (FBS; Gibco, USA), penicillin (100 U/mL) and streptomycin (100 mg/mL). Eighty percent confluent cells were used for transfection with the recombinant genome and fully confluent cells were infected with the recombinant virus for propagation and production. Vero cells (ATTC, CCL-81) were cultured in Minimum Essential Medium (MEM; Gibco) containing 10% FBS. Live attenuated PPRV vaccine strain Nigeria/75/1 (Nig/75/1) was obtained from the China Institute of Veterinary Drug Control. CAV-2 strain YCA 18 was isolated by Xia et al. [33]. A complete PPRV cDNA derived from a PCR product of PPRV strain China/Tibet/Geg/
07-30 (GenBank accession no. EF905304) was kindly provided by the China Animal Health and Epidemiology Center. Plasmid pPOLYII-CAV-2, containing the whole genome of canine adenovirus type-2, was constructed and described by Zhang et al. [34]; it was chosen for use here based on its features as an infectious plasmid that can produce canine adenovirus particles after transfection of MDCK cells.

The Construction of pPolyII-CAV-ΔE3-H

The open reading frame (ORF) of the PPRV glycoprotein gene H was amplified by RT-PCR using the following primer pair, which introduced KpnI and XhoI restriction enzyme sites at the respective 5’-termini (underlined): forward primer H1, 5’-CCGGTACCATGGCGCAAAAGGGAAAG-3’ (the complete Kozak sequence in bold); reverse primer H2, 5’-GGCGTCTGAGTCAGACTGGATTACATGTTGACCTC-3’. The PCR product of the H gene was subcloned into the pMD18-T vector (TaKaRa, China), and the resultant pMD18-T-H vector was sequenced by the UN Corporation of Shanghai, China. The PCR product of the H gene was subcloned into the pMD18-T vector (TaKaRa, China), and the resultant pMD18-T-H vector was sequenced by the UN Corporation of Shanghai, China. The 4.8 kb KpnI fragment containing the E3 region from pPolyII-CAV-2 was first cloned into pVAX1 (Invitrogen) to generate pVAX-ΔE3. The H sequence was released with KpnI and XhoI from pMD18-T-H and cloned into the KpnI/XhoI sites of pVAX1 to generate pVAX-H. The MluI/HindIII fragment of pVAX-H, containing the H cDNA expression cassette driven by the cytomegalovirus (CMV) immediate early promoter with BGH polyadenylation signals at the other end of the gene, was blunted using a DNA blunting kit (TaKaRa) and directionally cloned into the SphI site of pVAX-ΔE3, forming the pVAXΔE3-H vector. The NruI and SalI double digest pVAXΔE3-H fragment containing the H expression cassette flanked with residual E3 sequences was cloned back into pPolyII-CAV-2 by replacing the fragment between the NruI and SalI sites, forming the final pPolyII-CAV-ΔE3-H plasmid (Fig. 1). The recombinant genome was purified for use in transfection. The preparation, cloning and identification of genes and recombinant plasmids were performed according to standard methods [35].

Transfection of the Recombinant Genome in MDCK Cells and Production of Recombinant virus

MDCK cells were transfected with recombinant genome pPolyII-CAV-ΔE3-H using Lipofectamine2000™ (Invitrogen), according to the manufacturer’s protocol. Briefly, MDCK cells (2.5×10⁵ cells/well) were cultured in six-well tissue culture plates (Nunc, USA). At approximately 70–80% confluence, supplemented medium was removed and cells were washed with OPTI-MEM (Gibco). Four micrograms of purified linearized recombinant virus genome were dissolved in 250 μL OPTI-MEM, and then mixed with 10 μL Lipofectamine2000™ dispersed in 250 μL OPTI-MEM and incubated at room temperature for 20 min. The transfection mix was then spread over the 80% confluent MDCK cells and incubated for six hours, when it was replaced by 2 mL complete DMEM (5% FBS). Transfected cells were incubated at 37°C and blind-passaged until cytopathic effects (CPE) appeared, when samples of cell lysates were collected for electron microscopic examination using negative staining with potassium phosphotungstate.

Western Blotting

The supernatant of the recombinant virus cell culture lysates was separated on 15% SDS-PAGE gels and the proteins were transferred onto a nitrocellulose membrane (Bio-Rad, USA). The proteins were probed with goat anti-PPRV antiserum (1:200) and horseradish peroxidase-labeled donkey anti-goat IgG antibody (1:5000; Sigma, USA), according to the protocols described elsewhere [36].

Immunofluorescence Analysis

To analyze expression of H protein on the surface of cells, MDCK cells were infected with CAV-2, rCAV-2-H, at a multiple of infection (m.o.i.) of 1 for 48 h. Afterwards, infected cells were fixed with 4% paraformaldehyde for 20 min at room temperature and treated with 0.1% Triton-X100. After washing three times with PBS, cells were incubated with goat anti-PPRV antiserum (1:200), followed by Alexa Fluor® 488-conjugated donkey anti-

Table 1. Experimental designs of the animal studies.

| Group | Vaccine          | Route | Dosage   | Dose   |
|-------|------------------|-------|----------|--------|
| A-1(n = 35) | rCAV-2-PPRV-H | IM    | 10⁶ TCID₅₀ | 2 doses, 3 weeks |
| A-2(n = 21) | rCAV-2-PPRV-H | IM    | 10⁶ TCID₅₀ | 2 doses, 3 weeks |
| B(n = 3)   | Attenuated      | IM    | 10⁶ TCID₅₀ | 2 doses, 3 weeks |
| C(n = 3)   | CAV-2           | IM    | 10⁶ TCID₅₀ | 2 doses, 3 weeks |

IM stands for intramuscular.

doi:10.1371/journal.pone.0037170.t001

Figure 3. Fluorescence microscopy analysis of PPRV H protein in recombinant virus-infected MDCK cells. MDCK cells were infected with rCAV-2-PPRV-H (A) or CAV-2 (B) at 1 m.o.i. Negative controls were untransfected cells (C). After 48 h, the infected cells were detected with goat anti-PPRV antiserum, followed by Alexa Fluor® 488-conjugated donkey anti-goat IgG and observed under fluorescence microscope.

doi:10.1371/journal.pone.0037170.g003

PPRV IM stands for intramuscular.
and stored at -20°C until analyzed. Supernatants (5% FBS, 200 U/mL penicillin and 200 mg/mL streptomycin) were collected and used to inoculate MDCK cell monolayers, according to the previously described protocol [37].

Canine Adenovirus Hemagglutination Inhibition (HI)

Canine adenovirus type-2 HI antibody titer was assayed according to the published protocol [38]. Briefly, goats from different groups were vaccinated with attenuated PPRV vaccine, rCAV-2-PPRV-H, or CAV-2 and the serum samples were collected at weeks 0-30 following the primary vaccination. Serial 2-fold dilutions of sera were mixed with 25 µL CAV-2, titer 4 HA units, with PBS (0.01 M, pH 7.2) as the control, and incubated at 37°C for 30 min. Then, 25 µL 1% human group O red blood cells suspended in PBS (pH 7.2) were added to each well and incubated at 37°C for 1 h. Titers were determined as the highest dilution showing at least partial agglutination.

Virus Neutralization Test (VNT)

VNT was performed according to the recommendations from the World Organization for Animal Health (formerly, the Office International des Epizooties). Briefly, the vaccine strain of PPRV (Nig 75/1) was grown in Vero cells. Aliquots of virus (100 TCID<sub>50</sub>) were incubated at 37°C for one hour with serial dilutions of the test or control sera (heat inactivated at 56°C for 30 min) and then were added to Vero cells growing in a flat-bottom 96-well tissue culture plate. Cells were observed microscopically for CPE starting at day 3 post-infection. The CPE recorded at day 3 was used for the calculation of PPRV virus neutralization (VNA) titers. Virus neutralization titer was defined as the highest serum dilution that inhibited CPE by at least 50%.

Lymphocyte Proliferation Assay

Individual goats from experimental groups were bled from the jugular vein at week 3 after the booster injection. Peripheral blood mononuclear cells (PBMCs) were prepared as previously described.

Table 2. Neutralizing Antibody titers against PPRV in goats immunized with attenuated PPRV vaccine, rCAV-2-H and CAV-2.

| Group | Weeks post-primary vaccination | 0 | 3 | 6 | 9 | 12 | 15 | 18 | 21 | 24 | 27 | 30 |
|-------|--------------------------------|---|---|---|---|----|----|----|----|----|----|----|
| A-1<sup>a</sup> | <1:2 | 1:32–1:64 | 1:64–1:128 | 1:64–1:128 | - | - | - | - | - | - | - |
| A-2<sup>a</sup> | <1:2 | 1:32–1:64 | 1:64–1:128 | 1:64–1:128 | 1:64–1:128 | 1:32–1:64 | 1:32–1:64 | 1:32–1:64 | 1:32–1:64 | 1:32–1:64 | 1:32–1:64 |
| B<sup>b</sup> | <1:2 | 1:64–1:128 | 1:128–1:256 | 1:128–1:256 | 1:128–1:256 | 1:128–1:256 | 1:128–1:256 | 1:128–1:256 | 1:128–1:256 | 1:128–1:256 | 1:128–1:256 | 1:128–1:256 |
| C<sup>c</sup> | <1:2 | <1:2 | <1:2 | <1:2 | <1:2 | <1:2 | <1:2 | <1:2 | <1:2 | <1:2 | <1:2 |

<sup>a</sup><sup>b</sup> P<0.05, <sup>b</sup><sup>ab</sup> P<0.05, <sup>ab</sup> P<0.05.

Table 3. HI antibody titers of CAV-2 in goats immunized with attenuated PPRV vaccine, rCAV-2-H and CAV-2.

| Group | Weeks post-primary vaccination | 0 | 3 | 6 | 9 | 12 | 15 | 18 | 21 | 24 | 27 | 30 |
|-------|--------------------------------|---|---|---|---|----|----|----|----|----|----|----|
| A-1   | <1:2 | 1:2–1:2<sup>2</sup> | 1.2<sup>2</sup>–1.2<sup>2</sup> | 1.2<sup>2</sup>–1.2<sup>2</sup> | - | - | - | - | - | - | - |
| A-2<sup>a</sup> | <1:2 | 1:2–1:2<sup>2</sup> | 1.2<sup>2</sup>–1.2<sup>2</sup> | 1.2<sup>2</sup>–1.2<sup>2</sup> | 1.2<sup>2</sup>–1.2<sup>2</sup> | 1.2<sup>2</sup>–1.2<sup>2</sup> | 1.2<sup>2</sup>–1.2<sup>2</sup> | 1.2<sup>2</sup>–1.2<sup>2</sup> | 1.2<sup>2</sup>–1.2<sup>2</sup> | 1.2<sup>2</sup>–1.2<sup>2</sup> | 1.2<sup>2</sup>–1.2<sup>2</sup> |
| B<sup>b</sup> | <1:2 | <1:2 | <1:2 | <1:2 | <1:2 | <1:2 | <1:2 | <1:2 | <1:2 | <1:2 | <1:2 |
| C<sup>c</sup> | <1:2 | 1:2<sup>2</sup>–1:2<sup>2</sup> | 1:2<sup>2</sup>–1:2<sup>2</sup> | 1:2<sup>2</sup>–1:2<sup>2</sup> | 1:2<sup>2</sup>–1:2<sup>2</sup> | 1:2<sup>2</sup>–1:2<sup>2</sup> | 1:2<sup>2</sup>–1:2<sup>2</sup> | 1:2<sup>2</sup>–1:2<sup>2</sup> | 1:2<sup>2</sup>–1:2<sup>2</sup> | 1:2<sup>2</sup>–1:2<sup>2</sup> | 1:2<sup>2</sup>–1:2<sup>2</sup> |

<sup>a</sup><sup>b</sup> P<0.05, <sup>b</sup><sup>ab</sup> P<0.05, <sup>ab</sup> P<0.05.

doi:10.1371/journal.pone.0037170.t003
Table 4. Proliferative responses of PBMC of goats immunized with attenuated PPRV vaccine, rCAV-2-PPRV-H, CAV-2 and PBS.

| Group | Mean stimulation index ± SD |
|-------|-----------------------------|
| Attenuated PPRV vaccine<sup>a</sup> | 2.89 ± 0.27 |
| rCAV-2-PPRV-H<sup>b</sup> | 2.75 ± 0.38 |
| CAV-2<sup>c</sup> | 2.65 ± 0.41 |
| PBS<sup>d</sup> | 1.18 ± 0.26 |

Lymphocyte proliferative responses were analyzed by using PBMC collected at the day three weeks after boosting. <sup>a</sup>P<0.05, <sup>b</sup>P>0.05, <sup>c</sup>SP>0.05, <sup>d</sup>SP<0.05, <sup>e</sup>SP<0.05, <sup>f</sup>SP<0.05, <sup>g</sup>SP<0.05.

Statistical Analysis

All data were conducted by two-way analysis of variance (ANOVA) and Student’s t-test, using SPSS v.13.0 software. A P-value of less than 0.05 was considered statistically significant.

Acknowledgments

We thank Medjaden Bioscience Limited for assisting in the preparation of this manuscript.

Author Contributions

Conceived and designed the experiments: JQ HH YR XH TW NF. Analyzed the data: JQ HH YG. Contributed reagents/materials/analysis tools: JQ YR HH XH GH. Performed the experiments: JQ YY YR HH YG. Wrote the paper: JQ HH.

References

1. Romero CH, Barrett T, Kittich WP, Bostock G, Black DN (1995) Protection of goats against peste des petits ruminants with recombinant capripoxviruses expressing the fusion and haemagglutinin protein genes of rinderpest virus. Vaccine 13: 56–40.
2. Lefèvre PC, Diollo A (1990) Peste des petits ruminants. Rev Sci Tech 9: 935–961.
3. Taylor WP, al Busaidy S, Barrett T (1990) The epidemiology of peste des petits ruminants in the Sultanate of Oman. Vet Microbiol 22: 341–352.
4. Roeder PL, Abraham G, Kenfe G, Barrett T (1994) Peste des petits ruminants in Ethiopia. Trop Anim Health Prod 26: 69–73.
5. Amjad H, Qamar ul F, Forsyth M, Barrett T, Rossiter PB (1996) Peste des petits ruminants in goats in Pakistan. Vet Rec 138: 119–119.
6. Singh RP, Saravanan P, Sreenivasan BP, Singh RK, Bandypadhyay SK (2004) Prevalence and distribution of peste des petits ruminants virus infection in small ruminants in India. Rev Sci Tech 23: 807–819.
7. Oskul A, Akca Y, Alkan F, Barrett T, Karasoglu T, et al. (2002) Prevalence, distribution, and host range of Peste des petits ruminants virus, Turkey. Emerg Infect Dis 8: 708–712.
8. Kwiatek O, Minet C, Grillet C, Hurad C, Carlsson E, et al. (2007) Peste des petits ruminants (PPR) outbreak in Tajikistan. J Comp Pathol 136: 111–119.
9. Wang Z, Bao J, Wu X, Liu Y, Li L, et al. (2009) Peste des petits ruminants in goats in Pakistan. Vet Res 38: 119–119.
10. Gibbs EP, Taylor WP, Lawman MJ, Bryant J (1979) Classification of peste des petits ruminants virus as the fourth member of the genus Morbillivirus. Intervirology 11: 268–274.
11. Jones L, Giavolini E, Salki JT, Brown G, Mclus C, et al. (1993) Protection of goats against peste des petits ruminants with a vaccinia virus double recombinant expressing the F and H genes of rinderpest virus. Vaccine 11: 961–964.
12. Das SC, Baron MD, Barrett T (2000) Recovery and characterization of a chimeric rinderpest virus with the glycoproteins of peste-des-petits-ruminants virus: homologous F and H proteins are required for virus viability. J Virol 74: 1093–1097.
13. Sinnathamby G, Renukaradhya GJ, Rajasekhar M, Nayak R, Shailla M (2001) Immune responses in goats to recombinant hemagglutinin-neuraminidase glycoprotein of Peste des petits ruminants virus: identification of a T cell determinant. Vaccine 19: 4816–4823.
14. Berge G, Minet C, Le Goff G, Barrett T, Nguengoa A, et al. (2003) Development of a dual recombinant vaccine to protect small ruminants against peste-des-petits-ruminants virus and capripoxviruses infections. J Virol 77: 1571–1577.
15. Taylor WP (1979) Protection of goats against peste-des-petits-ruminants with attenuated rinderpest virus. Rev Vet Sci 27: 321–324.
16. Diasio A, Taylor WP, Lefèvre PC, Provost A (1989) [Attenuation of a strain of rinderpest virus; potential homologous live vaccine]. Rev Elev Med Vet Pays Trop 42: 311–319.
17. Anderson J, McKay JA (1994) The detection of antibodies against peste des petits ruminants virus in cattle, sheep and goats and the possible implications to rinderpest control programmes. Epidemiol Infect 112: 225–231.
18. Diasio A, Minet C, Le Goff G, Berge G, Albina E, et al. (2007) The threat of peste des petits ruminants: progress in vaccine development for disease control. Vaccine 25: 5394–5397.
19. Tatsi N, Erol HCJ (2004) Adenoviruses as vaccine vectors. Molecular Therapy 10: 616–629.
20. Croyde MA, Patel A, Tran KN, Gray M, Zhang Y, et al. (2008) Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS One 3: e5340.
21. Matthews QL, Fatima A, Tang Y, Perry BA, Tsutsu Y, et al. (2010) HIV antigen incorporation within adenovirus hexon hypervariable 2 for a novel HIV vaccine approach. PLoS One 5: e11615.
22. Morrison MD, Reid D, Onions D, Spibey N, Nicolison L (2002) Generation of E3-deleted canine adenoviruses expressing canine parvovirus capsid by homologous recombination in bacteria. Virology 293: 26–30.
23. Hu RL, Liu Y, Zhang SF, Zhang F, Fooks AR (2007) Experimental immunization of cats with a recombinant rabies-canine adenovirus vaccine elicits a long-lasting neutralizing antibody response against rabies. Vaccine 25: 5301–5307.
24. Hu R, Zhang S, Fooks AR, Yuan H, Liu Y, et al. (2006) Prevention of rabies virus infection in dogs by a recombinant canine adenovirus type-2 encoding the rabies virus glycoprotein. Microbes Infect 8: 1090–1097.
25. Yang S, Xia X, Qiao J, Liu Q, Chang S, et al. (2005) Complete protection of cats against feline panleukopenia virus challenge by a recombinant canine adenovirus type 2 expressing VP2 from FPV. Vaccine 26: 1462–1467.
26. Charlton KM, Artois M, Prevec L, Campbell JB, Casey GA, et al. (1992) Oral rabies vaccination of skunks and foxes with a recombinant human adenovirus vaccine. Arch Virol 126: 169–179.
27. Liu Y, Zhang S, Ma G, Zhang F, Hu R (2008) Efficacy and safety of a live canine adenovirus-vectorized rabies virus vaccine in swine. Vaccine 26: 5365–5372.
28. Sinnathamby G, Renukaradhya GJ, Rajasekhar M, Nayak R, Shailla M (2001) Immune responses in goats to recombinant hemagglutinin-neuraminidase glycoprotein of Peste des petits ruminants virus: identification of a T cell determinant. Vaccine 19: 4816–4823.
29. OIE BB (2008) Manual of diagnostic tests and vaccines for terrestrial animals. 2008 Edition.
30. Baron MD, Foster-Cuevas M, Baron J, Barrett T (1999) Expression in cattle of epitopes of a heterologous virus using a recombinant rinderpest virus. J Gen Virol 80 (Pt 6): 2031–2039.
31. Berinstein A, Tami C, Taboga O, Sminaart E, Carrillo E (2000) Protective immunity against foot-and-mouth disease virus induced by a recombinant vaccinia virus vaccine. Vaccine 18: 2231–2236.
32. Saravanan P, Sen A, Balamurugan V, Rajak KK, Bhanuprakash V, et al. (2010) Comparative efficacy of peste des petits ruminants (PPR) vaccines. Biologicals 38: 479–485.
33. Xia X, Fang Q, Huang G (2000) Isolation and identification of a canine adenovirus avirulent strain. Chin J Vet Med 34: 1–4.
34. Shou-feng Z, Rong-liang H, Jian-qiang N, Xian-zhu X (2002) Cloning and identification of the full length infectious genome of canine adenovirus type-2. Chinese Journal of Veterinary Science 06.
35. Sambrook J, Russell DW (2006) The condensed protocols from Molecular cloning: a laboratory manual. Harbor ColdSpring, ed. N.Y.: Cold Spring Harbor Laboratory Press v, 800 p.
36. Burnette WN (1981) "Western blotting": electrophoretic transfer of proteins from sodium dodecyl sulfate-polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radiiodinated protein A. Anal Biochem 112: 195–203.
37. Tham KM, Horner GW, Hunter R (1998) Isolation and identification of canine adenovirus type-2 from the upper respiratory tract of a dog. N Z Vet J 46: 102–105.
38. Schmidt NJ, Lennette EH, King CJ (1966) Neutralizing, hemagglutination-inhibiting and group complement-fixing antibody responses in human adenovirus infections. The Journal of Immunology 97: 64.
39. Xiao S, Chen H, Fang L, Liu C, Zhang H, et al. (2004) Comparison of immune responses and protective efficacy of suicidal DNA vaccine and conventional DNA vaccine encoding glycoprotein C of pseudorabies virus in mice. Vaccine 22: 345–351.